All In Biotech

NDA 017555 · Organon

Sinemet

Carbidopa, Levodopa · Oral · Aromatic Amino Acid Decarboxylation Inhibitor; Aromatic Amino Acid

NovelPriority review

Last checked: Nov 20, 2026Latest source record: Mar 19, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1975

May 2, 1975

Approved uses

1

Original approval plus efficacy supplements

Registered trials

262

53 Phase 3, 16 recruiting

FAERS reports

25,020

16,321 serious, 3,348 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Aug 1, 2026.

INDICATIONS AND USAGE SINEMET is indicated in the treatment of Parkinson's disease, post-encephalitic parkinsonism, and symptomatic parkinsonism that may follow carbon monoxide intoxication or manganese intoxication. Carbidopa allows patients treated for Parkinson's disease to use much lower doses of levodopa. Some patients who responded poorly to levodopa have improved on SINEMET. This is most likely due to decreased peripheral decarboxylation of levodopa caused by administration of carbidopa rather than by a primary effect of carbidopa on the nervous system. Carbidopa has not been shown to enhance the intrinsic efficacy of levodopa. Carbidopa may also reduce nausea and vomiting and permit more rapid titration of levodopa.

Mechanism: Mechanism of Action Parkinson's disease is a progressive, neurodegenerative disorder of the extrapyramidal nervous system affecting the mobility and control of the skeletal muscular system. Its characteristic features include resting tremor, rigidity, and bradykinetic movements. Symptomatic treatments, such as levodopa therapies, may permit the patient better mobility. Current evidence indicates that symptoms of Parkinson's disease are related to depletion of dopamine in the corpus striatum. Administration of dopamine is ineffective in the treatment of Parkinson's disease apparently because...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • May 2, 1975 Original approval · Type 1 - New Molecular Entity and Type 4 - New Combination · priority review
3 products under this application
  • SINEMET · CARBIDOPA 25MG; LEVODOPA 250MG · TABLET, ORAL · Prescription · TE AB
  • SINEMET · CARBIDOPA 25MG; LEVODOPA 100MG · TABLET, ORAL · Prescription · TE AB
  • SINEMET · CARBIDOPA 10MG; LEVODOPA 100MG · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Carbidopa" as an intervention, any sponsor and status, largest first.

All 262 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • fall2,405
  • hallucination2,404
  • drug ineffective2,286
  • dyskinesia1,596
  • death1,564
  • parkinson^s disease1,453
  • tremor1,453
  • confusional state1,445
  • dizziness1,301
  • nausea1,263
  • gait disturbance1,262
  • fatigue1,227

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004487
2005492
2006558
2007559
2008826
2009506
2010678
2011617
2012637
2013537
2014616
2015854
20161,389
20172,063
20181,978
20191,841
20202,202
20211,858
20221,478
20231,074
20241,093
20251,579
20261,098

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Sinemet (Carbidopa/Levodopa)

2024 spending

$307K

Beneficiaries

222

844 claims

Per beneficiary

$1,382

$1.29 per unit

View as table
YearSpending
2020$0
2021$11,822
2022$148,238
2023$279,344
2024$306,877

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 584 on PubMed

Sponsor: Organon

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.